Appointment Brings Over Ten Years as a CRO Executive
Tango Biosciences, Inc., the premier contract research organization for custom affinity reagents by phage display, announced the appointment of Zachary Gurard-Levin, PhD, to its board of directors effective immediately.
Gurard-Levin brings over two decades of experience in assay development and driving successful research programs for biotech and pharma companies, including ten years as an executive at a drug discovery CRO. He is the founder and managing director of Tesserae Innovations LLC, an organization that specializes in developing data-driving research plans, amplifying business development, and communicating value with clarity and confidence to ensure life science companies achieve their full commercial potential. He is also a board member of the Society for Laboratory Automation and Screening (SLAS).
“Dr. Gurard-Levin’s in-depth experience in commercializing innovative technologies and expertise in CRO technical marketing and effective communication will support our growth strategy in custom affinity reagents and binding assays,” states Michael Scholle, CEO for Tango Biosciences. “His expertise in developing creative solutions for high-quality assays and a vast network within the life science industry will be invaluable to Tango Biosciences.”
“I am thrilled to be on the board of directors and help guide Tango Biosciences as it expands its commercial operation and adds new capabilities to accelerate the development of world-class peptides and antibodies,” adds Gurard-Levin.
###